Comparative Pharmacology
Head-to-head clinical analysis: ASPARLAS versus HYDASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASPARLAS versus HYDASE.
ASPARLAS vs HYDASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Asparaginase (ASPARLAS) hydrolyzes L-asparagine to L-aspartic acid and ammonia, depleting circulating asparagine. Leukemic cells with low asparagine synthetase activity rely on exogenous asparagine; depletion inhibits protein and nucleic acid synthesis, leading to cell death.
HYDASE (hyaluronidase) hydrolyzes hyaluronic acid, a glycosaminoglycan in the extracellular matrix, thereby increasing tissue permeability and facilitating the dispersion and absorption of injected fluids or drugs.
Intravenous (IV) or intramuscular (IM) injection: 2,500 IU/m² every 14 days as a component of multi-agent chemotherapy. Administer IV over 1-2 hours in 100 mL of 0.9% sodium chloride.
Intravenous, intramuscular, or subcutaneous: 150-300 units (0.5-1 mL) as a single dose or divided into multiple doses to facilitate hydration and dispersion of other injected drugs. Frequency: as needed based on clinical indication, up to every 2-3 days.
None Documented
None Documented
The terminal elimination half-life is approximately 25.7 days (range 17.8–33.6 days) in children and 22.0 days in adults, allowing for dosing every 2 weeks instead of 3 times per week as with native E. coli asparaginase.
2 to 5 minutes intravenously; rapidly inactivated by proteases in plasma and tissues, resulting in ultra-short duration.
Calaspargase pegol (ASPARLAS) is eliminated via the reticuloendothelial system; renal excretion is negligible (<2% unchanged), and biliary/fecal excretion has not been quantified. The pegylated asparaginase is cleared through proteolytic degradation.
Primarily renal; <1% excreted unchanged in urine; extensive metabolism via proteolysis to amino acids and peptides.
Category C
Category C
Antineoplastic, Enzyme
Enzyme